	US 11,866,465 B2
	Oligomeric particle reagents and methods of use thereof
Thomas Schmidt, Munich (DE); Christian Stemberger, Munich (DE); Tom Kowski, Seattle, WA (US); and Ken Prentice, Seattle, WA (US)
Assigned to Juno Therapeutics GmbH, Munich (DE)
Appl. No. 16/608,796
Filed by Juno Therapeutics GmbH, Munich (DE)
PCT Filed Apr. 27, 2018, PCT No. PCT/IB2018/000507 § 371(c)(1), (2) Date Oct. 25, 2019, PCT Pub. No. WO2018/197949, PCT Pub. Date Nov. 1, 2018.
Claims priority of provisional application 62/491,245, filed on Apr. 27, 2017.
Prior Publication US 2021/0032297 A1, Feb. 4, 2021
Int. Cl. C07K 14/36 (2006.01); C07K 1/16 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01)

CPC C07K 14/36 (2013.01) [A61K 47/6898 (2017.08); C07K 1/16 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); A61K 2039/625 (2013.01); C07K 2317/55 (2013.01)]

56 Claims

1. A multimerized oligomeric particle reagent that is in soluble form and comprises (i) an oligomer of between 1,500 and 7,500 tetramers of a streptavidin molecule or a streptavidin mutein molecule and (ii) a receptor-binding agent that binds to a receptor expressed on the surface of a target cell, wherein:

the receptor-binding agent comprises a streptavidin-binding peptide that is reversibly bound to one or more binding sites of the streptavidin or streptavidin mutein molecules of the oligomer; and

the receptor-binding agent is a stimulatory agent, wherein binding of the receptor-binding agent to the receptor induces a stimulatory signal in the target cell.